VVT Med Announces Positive Clinical Data for ScleroSafe® in Indian Journal of Vascular and Endovascular Surgery

By Azon Vault On May 1, 2026

Introduction

VVT Med has just released promising clinical results for its proprietary drug‑delivery platform ScleroSafe®. The data, now peer‑reviewed and published in the Indian Journal of Vascular and Endovascular Surgery, highlight improved outcomes for patients undergoing minimally invasive vascular procedures. This breakthrough offers a fresh perspective on treating chronic venous diseases and adds a valuable tool to the endovascular toolbox.

Key Findings from the Study

Study Design

Multi‑center, prospective trial involving 150 patients across three major Indian hospitals.
Participants received ScleroSafe® as an adjunct to standard balloon angioplasty for superficial venous insufficiency.
Primary endpoints: vein occlusion rate, safety profile, and patient‑reported pain scores.

Results at a Glance

Occlusion rate: 92% at 6‑month follow‑up, compared with 78% for conventional sclerosants.
Complication rate: 1.3% minor adverse events; no major complications reported.
Pain reduction: Mean visual analogue scale (VAS) score dropped from 6.2 pre‑procedure to 1.8 post‑procedure.
Patient satisfaction score increased by 27% versus control group.

Why ScleroSafe® Stands Out

ScleroSafe® combines a proprietary polymer matrix with a low‑dose sclerosant, delivering a controlled release that maximizes endothelial damage while minimizing systemic exposure. The technology brings three major advantages:

Targeted action: The matrix adheres to the vein wall, ensuring the sclerosant remains localized.
Reduced pain: Controlled release softens the inflammatory response, leading to lower VAS scores.
Enhanced safety: Minimal systemic absorption translates to fewer allergic or toxic reactions.

Implications for Vascular Practitioners

For clinicians treating chronic venous insufficiency, varicose veins, or post‑thrombotic syndrome, ScleroSafe® offers a compelling alternative to traditional foam or liquid sclerosants. The data suggest:

Higher long‑term vein closure rates, potentially reducing repeat interventions.
Shorter recovery times, allowing patients to resume daily activities sooner.
Improved patient experience, which can translate into higher clinic satisfaction scores.

Next Steps and Availability

VVT Med plans to submit the results to regulatory bodies in the United States, Europe, and Asia by Q4 2026. Pending approval, the company expects to launch ScleroSafe® commercially in early 2027, with an initial focus on high‑volume vascular centers.

Conclusion

The peer‑reviewed publication of positive clinical data in a respected journal underscores the potential of ScleroSafe® to reshape endovascular treatment protocols. As more physicians adopt this technology, patients stand to benefit from safer, more effective venous interventions.